Research Study

An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis
Principal Investigator 
Robert Carruthers

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT02688985
Status 
Closed for Recruitment
Study Start/End 
Nov 7, 2016 to Sep 1, 2023
Locations 
UBC Hospital
Name/Title 
Jenon Valentine, Clinical Research Coordinator
Phone 
604-822-1758
Email Address 
jenon.valentine@ubc.ca
Purpose of Study 

This is an exploratory biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-Cell biology in relapsing multiple sclerosis (RMS). 

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.